Cardiac Science and Gust Bardy launch innovation center to develop cost-effective medical products and services

Cardiac Science Corporation (Nasdaq: CSCX), a global leader in automated external defibrillator (AED) and diagnostic cardiac monitoring devices, has joined with Gust Bardy, MD to create an innovation center focused on the development and commercialization of simple, cost-effective medical products and services that positively impact public health.

"Dr. Bardy shares our vision for the future of medicine and the growing importance of primary, remote, and self-directed care," said Dave Marver, Cardiac Science president and chief executive officer. "He is a proven thought-leader, researcher, clinician, and entrepreneur. We are pleased to forge this long-term relationship with Dr. Bardy to drive innovation and create value."

Under the agreement, Dr. Bardy will lead the Innovation Center within Cardiac Science to develop and commercialize advancements in medical technology and services. The Innovation Center will join Cardiac Science resources with Dr. Bardy's network of physician and research colleagues to focus on novel developments that simplify patient care with improved outcomes.

Dr. Bardy currently leads the Seattle Institute for Cardiovascular Research, where he served as Director and Primary Investigator for several significant trials in cardiology, including the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) and the Home AED Trial (HAT). He is also founder and board member of Cameron Health, Inc. and is clinical professor of medicine in cardiology and cardiac electrophysiology at University of Washington. Dr. Bardy has obtained more than 350 patents worldwide.

"With their broad reach into primary care and general cardiology offices, Cardiac Science is an ideal partner. I am passionate about making it easier for patients to access medical care and effectively navigate the healthcare system," said Gust Bardy, MD. "Dave and the team at Cardiac Science embrace change. I'm excited to be working with them and look forward to bringing many new ideas to physicians and their patients."

Source:

Cardiac Science Corporation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Patient-derived organoids: Transforming cancer research and personalized medicine